Total Payments
$2,960
2024 Payments
$408.13
Companies
18
Transactions
163
Medicare Patients
952
Medicare Billing
$163,394
Payment Breakdown by Category
Food & Beverage$2,906 (98.2%)
Education$33.62 (1.1%)
Other$20.00 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,906 | 160 | 98.2% |
| Education | $33.62 | 2 | 1.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $20.00 | 1 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $1,726 | 102 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $230.41 | 9 | $0 (2024) |
| Janssen Biotech, Inc. | $179.51 | 9 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $165.16 | 9 | $0 (2021) |
| Boston Scientific Corporation | $153.71 | 7 | $0 (2022) |
| PFIZER INC. | $87.21 | 4 | $0 (2024) |
| Gilead Sciences, Inc. | $84.17 | 5 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $76.92 | 4 | $0 (2020) |
| INTERCEPT PHARMACEUTICALS, INC. | $73.32 | 4 | $0 (2023) |
| Valeant Pharmaceuticals North America LLC | $29.89 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $408.13 | 21 | ABBVIE INC. ($248.88) |
| 2023 | $604.04 | 32 | AbbVie Inc. ($429.74) |
| 2022 | $380.98 | 22 | ABBVIE INC. ($339.64) |
| 2021 | $255.25 | 16 | AbbVie Inc. ($157.10) |
| 2020 | $253.88 | 13 | AbbVie Inc. ($132.85) |
| 2019 | $401.56 | 19 | AbbVie, Inc. ($122.44) |
| 2018 | $325.34 | 23 | AbbVie, Inc. ($167.94) |
| 2017 | $330.63 | 17 | AbbVie, Inc. ($127.03) |
All Payment Transactions
163 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | ABBVIE INC. | CREON (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $20.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/04/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $3.00 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $29.25 | General |
| Category: INTERNAL MEDICINE | ||||||
| 09/16/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $8.02 | General |
| Category: IMMUNOLOGY | ||||||
| 08/13/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $13.30 | General |
| Category: IMMUNOLOGY | ||||||
| 07/26/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.98 | General |
| Category: IMMUNOLOGY | ||||||
| 07/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $26.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 07/10/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: IMMUNOLOGY | ||||||
| 06/26/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: IMMUNOLOGY | ||||||
| 05/17/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: IMMUNOLOGY | ||||||
| 05/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $25.20 | General |
| Category: INTERNAL MEDICINE | ||||||
| 04/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $10.23 | General |
| Category: IMMUNOLOGY | ||||||
| 03/27/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Education | In-kind items and services | $19.12 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/26/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ, HUMIRA | Food and Beverage | In-kind items and services | $9.53 | General |
| Category: IMMUNOLOGY | ||||||
| 03/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $26.47 | General |
| Category: IMMUNOLOGY | ||||||
| 03/14/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: INTERNAL MEDICINE | ||||||
| 02/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: IMMUNOLOGY | ||||||
| 01/11/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: IMMUNOLOGY | ||||||
| 01/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: INTERNAL MEDICINE | ||||||
| 01/02/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $29.49 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2023 | AbbVie Inc. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $18.86 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2023 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $27.70 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/10/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: IMMUNOLOGY | ||||||
| 10/24/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $23.16 | General |
| Category: IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 239 | 388 | $128,290 | $36,881 |
| 2022 | 6 | 255 | 465 | $168,379 | $50,661 |
| 2021 | 6 | 264 | 482 | $171,091 | $49,816 |
| 2020 | 7 | 194 | 376 | $87,485 | $26,037 |
Total Patients
952
Total Services
1,711
Medicare Billing
$163,394
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 92 | 216 | $43,200 | $13,602 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 57 | 82 | $22,140 | $8,909 | 40.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 35 | 35 | $9,625 | $5,011 | 52.1% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2023 | 13 | 13 | $23,400 | $4,168 | 17.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 13 | 13 | $23,400 | $3,080 | 13.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 29 | 29 | $6,525 | $2,111 | 32.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 97 | 266 | $53,200 | $17,015 | 32.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Office | 2022 | 30 | 31 | $55,800 | $11,223 | 20.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 89 | $23,879 | $9,323 | 39.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Office | 2022 | 13 | 13 | $19,000 | $5,606 | 29.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $9,075 | $4,715 | 52.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 33 | 33 | $7,425 | $2,780 | 37.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 103 | 279 | $55,756 | $17,099 | 30.7% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Office | 2021 | 29 | 29 | $52,200 | $10,779 | 20.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 51 | 93 | $25,110 | $9,054 | 36.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Office | 2021 | 14 | 14 | $21,550 | $6,126 | 28.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 28 | 28 | $7,700 | $3,603 | 46.8% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 39 | 39 | $8,775 | $3,155 | 36.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 66 | 191 | $38,200 | $10,451 | 27.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 39 | 78 | $21,060 | $6,631 | 31.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 22 | 22 | $6,050 | $2,477 | 40.9% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 14 | 16 | $4,400 | $2,081 | 47.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 29 | $7,975 | $1,948 | 24.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 24 | 24 | $5,400 | $1,858 | 34.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 12 | 16 | $4,400 | $591.07 | 13.4% |
About Dr. Jonathan David, MD
Dr. Jonathan David, MD is a Gastroenterology healthcare provider based in Tuckahoe, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1922004241.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan David, MD has received a total of $2,960 in payments from pharmaceutical and medical device companies, with $408.13 received in 2024. These payments were reported across 163 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($2,906).
As a Medicare-enrolled provider, David has provided services to 952 Medicare beneficiaries, totaling 1,711 services with total Medicare billing of $163,394. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Tuckahoe, NY
- Active Since 06/22/2005
- Last Updated 07/29/2010
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1922004241
Products in Payments
- RINVOQ (Biological) $639.00
- Humira (Biological) $417.41
- HUMIRA (Biological) $324.76
- SKYRIZI (Biological) $303.76
- ENTYVIO (Biological) $230.41
- STELARA (Biological) $179.51
- ZEPATIER (Drug) $104.30
- GENERAL ENDOCHOICE (Device) $93.09
- XELJANZ (Drug) $87.21
- UCERIS TABLETS (Drug) $64.71
- DIFICID (Drug) $60.86
- OCALIVA (Drug) $56.62
- XIFAXAN (Drug) $42.10
- CREON (Drug) $40.69
- GENERAL - ENDOCHOICE (Device) $29.08
- TERLIVAZ (Drug) $28.25
- HADLIMA (Drug) $19.30
- ZYMFENTRA (Biological) $19.12
- SUPREP (Drug) $18.20
- VIBERZI (Drug) $18.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.